Report of Foreign Issuer (6-k)
March 31 2020 - 8:26AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
March 2020
Commission file number: 001-36288
Akari
Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
Tel: (646) 448-8743
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On March 31, 2020,
Akari Therapeutics, Plc (the “Company”) issued a press release announcing its financial results for the fourth quarter
and full year ended December 31, 2019, as well as recent business highlights. A copy of the press release is attached hereto as
Exhibit 99.1 and incorporated herein by reference.
The statements under
“Fourth Quarter and Full Year 2019 Financial Results”, the accompanying financial statements and ““Forward-Looking
Statements” of Exhibit 99.1 are hereby incorporated by reference into all effective registration statements filed by the
Company under the Securities Act of 1933.
Exhibit No.
|
99.1
|
Press
release dated March 31, 2020
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Akari Therapeutics, Plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
By:
|
/s/ Clive Richardson
|
|
|
Name:
|
Clive Richardson
|
|
|
|
Chief Executive Officer
and Chief Operating Officer
|
|
Date: March 31, 2020
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024